Gilles Salles is a Professor at the University Claude Bernard de Lyon and Head of the the Department of Haematology of the Hospices Civils de Lyon, at the Centre Hospitalier Lyon-Sud, Lyon, France. He is also the head of the Research Unit ‘Indolent B cell Proliferations”’ at the University of Lyon, affiliated with the CNRS. He served as Chairman of the Scientific Committee of the GELA (Groupe d’Etude des Lymphomes de l’Adulte) until 2007 and then as vice-president of this group until 2012 ; he is now the first chairman of LYSA (The Lymphoma Study Association), the recently created cooperative group that merged GELA and GOELAMS lymphoma activities. He is also a member of several professional societies, including the American Society of Hematology, the American Society of Clinical Oncology and the European Hematology Association. He serves as vice-president for research in the board of Directors of the Lyon University Hospitals (Hospices Civils de Lyon). Professor Salles has been especially interested in the clinical and biological study of malignant lymphoma – major focuses of his work include the description and validation of prognostic factors as well as clinical trials in indolent lymphomas. He has been involved as a coordinator or co-investigator in many clinical trials and studies within his field, and has published numerous articles in international peer-reviewed journals.